医学档案

  • 国际标准期刊号: 1698-9465
  • 期刊 h 指数: 26
  • 期刊引用分数: 9.83
  • 期刊影响因子: 7.03
索引于
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 引用因子
  • 西马戈
  • 电子期刊图书馆
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
分享此页面

抽象的

Efecto de las Estatinas sobre la Concentración de Vitamina D Sérica: Revisión

José Luis Mansur

Statins are very effective lipid-lowering agents and used in prevention of cardiovascular diseases, which also have effects "pleiotropic". It has been reported that its use can increase the serum level of vitamin D, although there are few studies at the moment, with different drugs and times of tracing. Both statins and vitamin D are metabolized by enzymes of the Cytochrome P450 system: simvastatin, atorvastatin and lovastatin for CYP3A4, fluvastatin for CYP2C9, while pravastatin and rosuvastatin is not eliminated by CYP enzymes. On the other hand vitamin D is an inducer of CYP3A4 and CYP2C9, which could explain the decrease in the frequency of muscle adverse effects of these drugs It has also been described that the pleiotropic effects of atorvastatin would be possible only in the presence of Vitamin D sufficiency. The possibility that both types of drugs have non-classical effects (the extra-bony vitamin D, and the pleiotropic effects of statins) and that these may be greater if both substances are in desirable values, opens a new perspective of prevention and of treatment of numerous pathologies.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证